A Phase II, Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability of Laquinimod in Adjunct to Glatiramer Acetate (GA) or Interferon-beta (IFN-β) in Relapsing Multiple Sclerosis (RMS) Subjects.

Trial Profile

A Phase II, Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability of Laquinimod in Adjunct to Glatiramer Acetate (GA) or Interferon-beta (IFN-β) in Relapsing Multiple Sclerosis (RMS) Subjects.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2013

At a glance

  • Drugs Laquinimod (Primary) ; Glatiramer acetate; Interferon beta
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 26 Aug 2013 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 15 Dec 2011 Planned initiation date changed from 1 Jul 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
    • 15 Dec 2011 Planned number of patients changed from 200 to 400 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top